Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3912]

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior...

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

CTC count as a prognostic marker for androgen deprivation plus orteronel or...

Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA

CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC ( Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA )

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation...

Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer ( Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in...

Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany

AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer ( Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany )

Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based...

Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy

Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer ( Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy )

COVID-19 and breast cancer: How should we treat our patients?

Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain

COVID-19 and breast cancer: How should we treat our patients? ( Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain )

Updated results from KEYNOTE-426 for metastatic kidney cancer

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

Updated results from KEYNOTE-426 for metastatic kidney cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )

HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve...

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve patients with advanced renal cell carcinoma ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )

Comment: JAVELIN-100 for metastatic urothelial cancer

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

Comment: JAVELIN-100 for metastatic urothelial cancer ( Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA )

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung...

Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung cancer ( Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA )

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer

Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer ( Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA )

PARP inhibitors in prostate cancer: Choices of tests and how to test?

Dr Kim Chi and Dr Alexander Wyatt

PARP inhibitors in prostate cancer: Choices of tests and how to test? ( Dr Kim Chi and Dr Alexander Wyatt )

More from ecancer